Evidence map›Paper›PMID 35238051›Full record

ReviewThe Journal of physiology2022

Controlling ion channel function with renewable recombinant antibodies.

Henry M Colecraft, James S Trimmer

Open access · greenAbstract readReview
In one paragraph

Review in The Journal of physiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Henry M ColecraftDepartment of Physiology and Cellular Biophysics, Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA.ORCID 0000-0002-2340-8899
James S TrimmerDepartment of Physiology and Membrane Biology, University of California Davis School of Medicine, Davis, CA, USA.ORCID 0000-0002-6117-3912
Columbia University · USUniversity of California, Davis · US

Funding

Recombinant Immunolabels for Nanoprecise Brain Mapping Across ScalesU24NS109113 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KARL Daniel MURRAY · 2018 to 2026
$9.9M
L-type channel trafficking and modulation in heartR01HL121253 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Henry M. Colecraft, Steven O Marx · 2014 to 2026
$8.4M
Ubiquitin Regulation of K Channels in Health and DiseaseR01HL142111 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI COLECRAFT, HENRY M. · 2018 to 2021
$2.3M
Mechanisms of Long QT Syndrome 1 in HeartR01HL122421 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI COLECRAFT, HENRY M. · 2016 to 2019
$1.8M
NHLBI NIH HHS R01 HL121253NHLBI NIH HHS R01 HL122421NHLBI NIH HHS R01 HL142111NINDS NIH HHS U24 NS109113
6 · The paper itself

Abstract

Selective ion channel modulators play a critical role in physiology in defining the contribution of specific ion channels to physiological function and as proof of concept for novel therapeutic strategies. Antibodies are valuable research tools that have broad uses including defining the expression and localization of ion channels in native tissue, and capturing ion channel proteins for subsequent analyses. In this review, we detail how renewable and recombinant antibodies can be used to control ion channel function. We describe the different forms of renewable and recombinant antibodies that have been used and the mechanisms by which they modulate ion channel function. We highlight the use of recombinant antibodies that are expressed intracellularly (intrabodies) as genetically encoded tools to control ion channel function. We also offer perspectives of avenues of future research that may be opened by the application of emerging technologies for engineering recombinant antibodies for enhanced utility in ion channel research. Overall, this review provides insights that may help stimulate and guide interested researchers to develop and incorporate renewable and recombinant antibodies as valuable tools to control ion channel function.

Indexed as

AntibodiesIon ChannelsAntibodiesIon Channelsantibodyintrabodyion channel modulationnanobodyscFv

Identifiers

PMID35238051
PMCPMC9058206
OpenAlexW4214884457

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.